LONDON (Monitoring Desk) According to Oxford University, which helped create the vaccine, a British trial of the AstraZeneca corona virus vaccine on children has been halted while regulators investigate the vaccine’s potential connection to blood clots. Although there are no safety issues in the pediatric clinical trial, the university said in a statement that it is waiting for more information from the MHRA (UK regulator) on its analysis of rare cases of thrombosis/thrombocytopaenia identified in children before giving any more vaccinations in the trial.
Parents and children should start attending all planned appointments, and if they have any concerns, they should contact the trial sites. After cases were first recorded in Norway and continental Europe, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom is one of several bodies around the world examining real-world data from the AstraZeneca launch to see whether there is a conclusive connection between the jab and a rare type of blood clot.
The findings of the WHO and the European Medicines Agency (EMA) will be released later this week. It is the latest drama to engulf AstraZeneca, which has already been dogged by controversy over its inability to supply promised doses to the European Union, as well as the effectiveness and safety profile of the vaccine.
Out of the 18 million doses administered in the UK, the MHRA recorded 30 cases of blood clotting, seven of which were fatal. Stella Kyriakides, the EU’s Health Commissioner, later reported that the EMA would make its decision “late Wednesday,” and that she was in “near touch” with the department. The EMA’s head of vaccine planning, Marco Cavaleri, was mentioned in Italian media as saying there was a “clear” link and that the agency would declare it within hours.